BioWorld Asia

Feb. 13, 2002

NeuroSearch, Ingelheim Enter $80M Alliance Around NS2330

Shares in NeuroSearch A/S surged more than 50 percent Friday on news of its largest ever deal, a US$80 million pact with Boehringer Ingelheim GmbH to develop its candidate Alzheimer’s and Parkinson’s drug, NS2330. (BioWorld International) Read More

Irish Government Backs EUR15M Biotech Life Sciences Seed Fund

Genetic Tests Predict Cancer Risks, Melanoma Study Shows

EU Officials Want Legislation Covering Tissue, Cell Implants

Proteom Raises £3M To Further Work Around Protein Interactions

Other News To Note

Transgene Says Restructuring In Place, Products Moving Along

Scancell Partners Antibody Drug In Asia With Korean Company

Metabolic Eyeing Phase IIb Trial In Obesity After Positive IIa Study

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...